Clinical Trial Update: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating neoadjuvant durvalumab and tremelimumab in combination with radiation for high-risk soft tissue sarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: TERMINATED